Acurx Pharmaceuticals, Inc.
ACXP
NASDAQ
Weiss Ratings | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Very Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -0.52 | |||
Price History | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -12.28% | |||
30-Day Total Return | -17.17% | |||
60-Day Total Return | -41.01% | |||
90-Day Total Return | -32.08% | |||
Year to Date Total Return | -40.57% | |||
1-Year Total Return | -28.18% | |||
2-Year Total Return | -34.87% | |||
3-Year Total Return | -- | |||
5-Year Total Return | -- | |||
52-Week High % Change | -78.00% | |||
52-Week Low % Change | 65.81% | |||
Price | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $8.82 | |||
52-Week Low Price | $1.17 | |||
52-Week Low Price (Date) | Oct 02, 2023 | |||
52-Week High Price (Date) | Oct 12, 2023 | |||
Valuation | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 30.57M | |||
Enterprise Value | 23.09M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -1.14 | |||
Earnings Per Share Growth | 2.37% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | 6.02 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | $2.38 | |||
Enterprise Value/EBITDA (TTM) | -- | |||
Enterprise Value/EBIT | -1.58 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 13.84M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 917 533 1469 | |||
Address | 259 Liberty Avenue Staten Island, NY 10305 | |||
Website | www.acurxpharma.com | |||
Country | United States | |||
Year Founded | 2017 | |||
Profitability | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -106.65% | |||
Return on Equity | -- | |||
Income Statement | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -- | |||
EBIT (TTM) | -14.58M | |||
Net Income (TTM) | -14.58M | |||
Net Income Avl. to Common (TTM) | -14.58M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | -56.87% | |||
EPS Diluted (TTM) | -1.14 | |||
EPS Diluted Growth (Q YOY) | -31.59% | |||
Balance Sheet | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 7.47M | |||
Cash Per Share (Q) | $0.54 | |||
Total Current Assets (Q) | 7.71M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 4.67M | |||
Current Ratio (Q) | 2.534 | |||
Book Value Per Share (Q) | $0.32 | |||
Total Assets (Q) | 7.71M | |||
Total Current Liabilities (Q) | 3.04M | |||
Total Debt (Q) | 0.00 | |||
Total Liabilities (Q) | 3.04M | |||
Total Common Equity (Q) | 4.67M | |||
Cash Flow | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -- | |||
Cash from Financing (TTM) | 8.16M | |||
Net Change in Cash (TTM) | -1.64M | |||
Levered Free Cash Flow (TTM) | -4.33M | |||
Cash from Operations (TTM) | -9.80M | |||